|
|
|
|
|
|
|
|
|
|
NEW YORK (Reuters Health) - The coauthor of a study that helped convince the European Commission on Friday to approve bevacizumab (Avastin) as an initial post-surgical treatment for advanced ovarian cancer predicted that some doctors may be reluctant to use the drug until mortality data become available in 2013.......
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.